Antibe Therapeutics, Inc.

Ordinary Shares International Reporting
OTCQX International
Verified Company Profile 5/26/2017
Contact Info
  • 15 Prince Arthur Avenue
  • Toronto, ONT M5R 1B2
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Dec 31, 2016 Interim Financial Report
CIK 0001583682
Fiscal Year End 3/31
OTC Marketplace OTCQX International
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Canada
Year of Inc. 2013
Employees 46 a/o Mar 31, 2017
Company Officers/Contacts
Daniel Legault CEO
John Wallace CSO
Alain Wilson CFO
Scott Curtis VP, Business Development
David Vaughan Chief Development Officer
Beth Chin Finance Manager
Company Directors
Walt Macnee Chairman
Roderick Flower
Daniel Legault
Samira Sakhia
John Wallace
Service Providers
Accounting/Auditing Firm
Ernst & Young
11th km National Road Athens-Lamia
Securities Counsel Investor Relations Firm

Not Available
Company History
  • Sponsored for OTCQX by Merriman Capital, Inc. on 9/15/2014.
ATBPF Security Details
Share Structure
Market Value1 $8,403,205 a/o Jun 23, 2017
Authorized Shares Unlimited a/o May 25, 2017
Outstanding Shares 113,098,314 a/o May 25, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 73,271,520 a/o May 25, 2017
Par Value Not Available
Shareholders of Record Not Available
Non US Stock Exchange Listing
ATE - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 4,559 (100%)
May 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security